Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Candice Abuso

Internal Medicine Harvey, LA Medical Doctor

NPI 1780670489 CMS profile 216999

2845 Manhattan Blvd, Harvey, LA 70058

Open in the dashboard

General payments

$3,546

249 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candice Abuso of Harvey, LA is reported in the CMS Open Payments database as having received $3,546 across 249 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $584 34
2024 General $408 27
2023 General $475 26
2022 General $127 7
2021 General $14 1
2019 General $1,938 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candice Abuso
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Candice Abuso were reported at $584. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Candice Abuso Internal Medicine median Middle half National median
2019 $1,938 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $14 $135 $37–$521 $132
2022 $127 $141 $42–$496 $149
2023 $475 $149 $45–$519 $160
2024 $408 $154 $47–$537 $164
2025 $584 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $644 40 payments
  2. Lilly USA, LLC $560 48 payments
  3. GlaxoSmithKline, LLC. $371 28 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $273 19 payments
  5. Pfizer Inc. $244 18 payments
  6. AstraZeneca Pharmaceuticals LP $226 13 payments
  7. Merck Sharp & Dohme Corporation $212 19 payments
  8. Novo Nordisk Inc $145 13 payments
  9. Sanofi-Aventis U.S. LLC $143 11 payments
  10. Janssen Pharmaceuticals, Inc $134 11 payments
  11. Other $593 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,540 248 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY $401 15 payments
  2. MOUNJARO $325 23 payments
  3. TRELEGY ELLIPTA $264 20 payments
  4. LINZESS $237 22 payments
  5. TRULICITY $235 25 payments
  6. JARDIANCE $235 25 payments
  7. ZEPBOUND $231 18 payments
  8. QULIPTA $195 8 payments
  9. FARXIGA $152 8 payments
  10. XARELTO $134 11 payments
  11. Other $3,092 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 147 drugs

Part D claims

11,512

Median for Internal Medicine: 777

Drug cost

$811,760

Median for Internal Medicine: $73,373

Branded share of claims

19.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 154 $188,082
Trulicity Dulaglutide Brand 69 $88,481
Mounjaro Tirzepatide Brand 65 $79,951
Jardiance Empagliflozin Brand 56 $67,168
Linzess Linaclotide Brand 51 $52,596
Januvia Sitagliptin Phosphate Brand 48 $49,038
Eliquis Apixaban Brand 57 $47,549
Xarelto Rivaroxaban Brand 19 $21,838
Tresiba Flextouch U-100 Insulin Degludec Brand 22 $19,263
Entresto Sacubitril/Valsartan Brand 16 $17,798

The 10 drugs with the highest cost, of 147 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$22,637

Medicare's payments for the services billed

Medicare patients

188

Average age 73

Services billed

453

135 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 37%
Ischemic heart disease 20%
Chronic kidney disease 16%
Depression 15%
Cancer 13%
Osteoporosis 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $90
$90 65 —
UBRELVY
  • AbbVie, Inc. $77
$77 — —
LINZESS
  • AbbVie, Inc. $41
  • Ironwood Pharmaceuticals, Inc $22
$63 51 —
ZEPBOUND
  • Lilly USA, LLC $51
$51 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $32
$32 56 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record